Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01272219




Registration number
NCT01272219
Ethics application status
Date submitted
6/01/2011
Date registered
7/01/2011
Date last updated
19/01/2018

Titles & IDs
Public title
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Scientific title
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Secondary ID [1] 0 0
2008-001049-24
Secondary ID [2] 0 0
NN8022-1839
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metabolism and Nutrition Disorder 0 0
Obesity 0 0
Condition category
Condition code
Diet and Nutrition 0 0 0 0
Obesity
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Metabolic and Endocrine 0 0 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo

Experimental: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) -

Experimental: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) -

Placebo comparator: Liraglutide Placebo, no Pre-diabetes -

Experimental: Liraglutide 3.0mg, Pre-diabetes -

Placebo comparator: Liraglutide Placebo, Pre-diabetes -


Treatment: Drugs: liraglutide
Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).

Treatment: Drugs: placebo
Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).

Treatment: Drugs: liraglutide
Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.

Treatment: Drugs: placebo
Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Fasting Body Weight
Timepoint [1] 0 0
Week 0, Week 56
Primary outcome [2] 0 0
Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.
Timepoint [2] 0 0
At Week 56
Primary outcome [3] 0 0
Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight
Timepoint [3] 0 0
At 56 weeks
Primary outcome [4] 0 0
Proportion of Subjects With Onset of Type 2 Diabetes
Timepoint [4] 0 0
At 160 weeks
Secondary outcome [1] 0 0
Change From Baseline in Waist Circumference (cm)
Timepoint [1] 0 0
Week 0, Week 56
Secondary outcome [2] 0 0
Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)
Timepoint [2] 0 0
Week 0, week 160
Secondary outcome [3] 0 0
Pre-diabetes Status After 56 Weeks of Treatment
Timepoint [3] 0 0
Week 0, Week 56
Secondary outcome [4] 0 0
Pre-diabetes Status in Subject With Pre-diabetes at Baseline After 160 Weeks of Treatment
Timepoint [4] 0 0
Week 0, week 160
Secondary outcome [5] 0 0
Mean Change From Baseline in Fasting Body Weight (Subjects With Pre-diabetes at Baseline)
Timepoint [5] 0 0
Week 0, week 160
Secondary outcome [6] 0 0
Proportion of Subjects Losing at Least 5% and Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight (Subjects With Pre-diabetes at Baseline)
Timepoint [6] 0 0
At 160 weeks
Secondary outcome [7] 0 0
Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)
Timepoint [7] 0 0
Week 56, Week 68
Secondary outcome [8] 0 0
Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)
Timepoint [8] 0 0
Week 0, Week 68

Eligibility
Key inclusion criteria
* Informed consent obtained
* Body Mass Index (BMI) of 30.0 kg/m^2 or above
* Body Mass Index (BMI) of 27 kg/m^2 or above in the presence of co-morbidities of treated or untreated dyslipidemia and/or hypertension
* Stable body weight
* Preceding failed dietary effort
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known type 1 or type 2 diabetes
* Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126 mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)
* Screening calcitonin of 50 ng/L or above
* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
* Personal history of non-familial medullary thyroid carcinoma
* History of acute or chronic pancreatitis
* Obesity induced by drug treatment
* Use of approved weight lowering pharmacotherapy
* Previous surgical treatment of obesity
* History of major depressive disorder or suicide attempt
* Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100 mmHg or above)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/03/2015
Sample size
Target
Accrual to date
Final
3731
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Novo Nordisk Investigational Site - University Of Sydney
Recruitment hospital [2] 0 0
Novo Nordisk Investigational Site - Woolloongabba
Recruitment hospital [3] 0 0
Novo Nordisk Investigational Site - Adelaide
Recruitment hospital [4] 0 0
Novo Nordisk Investigational Site - Heidelberg West
Recruitment postcode(s) [1] 0 0
2006 - University Of Sydney
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
5005 - Adelaide
Recruitment postcode(s) [4] 0 0
3081 - Heidelberg West
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autónoma de Bs As
Country [29] 0 0
Argentina
State/province [29] 0 0
Ciudad Autónoma de BsAs
Country [30] 0 0
Argentina
State/province [30] 0 0
Ciudad de Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Mar del Plata
Country [32] 0 0
Austria
State/province [32] 0 0
Graz
Country [33] 0 0
Austria
State/province [33] 0 0
Salzburg
Country [34] 0 0
Austria
State/province [34] 0 0
Wien
Country [35] 0 0
Belgium
State/province [35] 0 0
Boussu
Country [36] 0 0
Belgium
State/province [36] 0 0
Edegem
Country [37] 0 0
Belgium
State/province [37] 0 0
Liège
Country [38] 0 0
Brazil
State/province [38] 0 0
Rio Grande Do Sul
Country [39] 0 0
Brazil
State/province [39] 0 0
Sao Paulo
Country [40] 0 0
Brazil
State/province [40] 0 0
Curitiba
Country [41] 0 0
Brazil
State/province [41] 0 0
São Paulo
Country [42] 0 0
Canada
State/province [42] 0 0
Alberta
Country [43] 0 0
Canada
State/province [43] 0 0
Newfoundland and Labrador
Country [44] 0 0
Canada
State/province [44] 0 0
Nova Scotia
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
Denmark
State/province [47] 0 0
Frederiksberg C
Country [48] 0 0
Denmark
State/province [48] 0 0
Hvidovre
Country [49] 0 0
Denmark
State/province [49] 0 0
Århus C
Country [50] 0 0
Finland
State/province [50] 0 0
Kuopio
Country [51] 0 0
Finland
State/province [51] 0 0
Oulu
Country [52] 0 0
Finland
State/province [52] 0 0
University Of Helsinki
Country [53] 0 0
Former Serbia and Montenegro
State/province [53] 0 0
Belgrade
Country [54] 0 0
France
State/province [54] 0 0
Antibes
Country [55] 0 0
France
State/province [55] 0 0
Lille
Country [56] 0 0
France
State/province [56] 0 0
PARIS cedex 13
Country [57] 0 0
France
State/province [57] 0 0
Paris
Country [58] 0 0
France
State/province [58] 0 0
Pierre-Bénite
Country [59] 0 0
France
State/province [59] 0 0
Saint Herblain
Country [60] 0 0
Germany
State/province [60] 0 0
Bad Nauheim
Country [61] 0 0
Germany
State/province [61] 0 0
Berlin
Country [62] 0 0
Germany
State/province [62] 0 0
Dresden
Country [63] 0 0
Germany
State/province [63] 0 0
Duisburg
Country [64] 0 0
Germany
State/province [64] 0 0
Freiburg
Country [65] 0 0
Germany
State/province [65] 0 0
Giessen
Country [66] 0 0
Germany
State/province [66] 0 0
Gifhorn
Country [67] 0 0
Germany
State/province [67] 0 0
Leipzig
Country [68] 0 0
Germany
State/province [68] 0 0
Mannheim
Country [69] 0 0
Germany
State/province [69] 0 0
Saint Ingbert
Country [70] 0 0
Hong Kong
State/province [70] 0 0
Shatin, New Territories
Country [71] 0 0
Hungary
State/province [71] 0 0
Budapest
Country [72] 0 0
Hungary
State/province [72] 0 0
Debrecen
Country [73] 0 0
India
State/province [73] 0 0
Karnataka
Country [74] 0 0
India
State/province [74] 0 0
Maharashtra
Country [75] 0 0
India
State/province [75] 0 0
Tamil Nadu
Country [76] 0 0
India
State/province [76] 0 0
Karnal
Country [77] 0 0
India
State/province [77] 0 0
Kerala
Country [78] 0 0
Ireland
State/province [78] 0 0
Dublin 9
Country [79] 0 0
Ireland
State/province [79] 0 0
Dublin
Country [80] 0 0
Ireland
State/province [80] 0 0
Galway
Country [81] 0 0
Israel
State/province [81] 0 0
Haifa
Country [82] 0 0
Israel
State/province [82] 0 0
Jerusalem
Country [83] 0 0
Israel
State/province [83] 0 0
Kfar Saba
Country [84] 0 0
Israel
State/province [84] 0 0
Ofakim
Country [85] 0 0
Israel
State/province [85] 0 0
Petah-Tikva
Country [86] 0 0
Israel
State/province [86] 0 0
Tel Hashomer
Country [87] 0 0
Israel
State/province [87] 0 0
Tel-Aviv
Country [88] 0 0
Italy
State/province [88] 0 0
Bologna
Country [89] 0 0
Italy
State/province [89] 0 0
Firenze
Country [90] 0 0
Italy
State/province [90] 0 0
Milano
Country [91] 0 0
Italy
State/province [91] 0 0
Padova
Country [92] 0 0
Italy
State/province [92] 0 0
Palermo
Country [93] 0 0
Italy
State/province [93] 0 0
Pisa
Country [94] 0 0
Italy
State/province [94] 0 0
Roma
Country [95] 0 0
Italy
State/province [95] 0 0
Siena
Country [96] 0 0
Mexico
State/province [96] 0 0
Hidalgo
Country [97] 0 0
Mexico
State/province [97] 0 0
Jalisco
Country [98] 0 0
Mexico
State/province [98] 0 0
México, D.F.
Country [99] 0 0
Mexico
State/province [99] 0 0
Tamaulipas
Country [100] 0 0
Mexico
State/province [100] 0 0
Durango
Country [101] 0 0
Mexico
State/province [101] 0 0
Monterrey
Country [102] 0 0
Netherlands
State/province [102] 0 0
Almere
Country [103] 0 0
Netherlands
State/province [103] 0 0
Amsterdam
Country [104] 0 0
Netherlands
State/province [104] 0 0
Beek
Country [105] 0 0
Netherlands
State/province [105] 0 0
Hengelo OV
Country [106] 0 0
Netherlands
State/province [106] 0 0
Hilversum
Country [107] 0 0
Netherlands
State/province [107] 0 0
Leidschendam
Country [108] 0 0
Netherlands
State/province [108] 0 0
Zwijndrecht
Country [109] 0 0
Norway
State/province [109] 0 0
Bergen
Country [110] 0 0
Norway
State/province [110] 0 0
Oslo
Country [111] 0 0
Norway
State/province [111] 0 0
Trondheim
Country [112] 0 0
Norway
State/province [112] 0 0
Tønsberg
Country [113] 0 0
Poland
State/province [113] 0 0
Bialystok
Country [114] 0 0
Poland
State/province [114] 0 0
Katowice
Country [115] 0 0
Poland
State/province [115] 0 0
Poznan
Country [116] 0 0
Poland
State/province [116] 0 0
Szczecin
Country [117] 0 0
Poland
State/province [117] 0 0
Warszawa
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Arkhangelsk
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Moscow
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Novosibirsk
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Tumen
Country [122] 0 0
Serbia
State/province [122] 0 0
Belgrade
Country [123] 0 0
South Africa
State/province [123] 0 0
Gauteng
Country [124] 0 0
South Africa
State/province [124] 0 0
Western Cape
Country [125] 0 0
Spain
State/province [125] 0 0
Almería
Country [126] 0 0
Spain
State/province [126] 0 0
Barcelona
Country [127] 0 0
Spain
State/province [127] 0 0
Madrid
Country [128] 0 0
Spain
State/province [128] 0 0
Santiago de Compostela
Country [129] 0 0
Spain
State/province [129] 0 0
Sevilla
Country [130] 0 0
Spain
State/province [130] 0 0
Valladolid
Country [131] 0 0
Switzerland
State/province [131] 0 0
Baden-Dättwil
Country [132] 0 0
Switzerland
State/province [132] 0 0
Bern
Country [133] 0 0
Switzerland
State/province [133] 0 0
Genève 14
Country [134] 0 0
Switzerland
State/province [134] 0 0
St. Gallen
Country [135] 0 0
Switzerland
State/province [135] 0 0
Zollikerberg
Country [136] 0 0
Turkey
State/province [136] 0 0
Ankara
Country [137] 0 0
Turkey
State/province [137] 0 0
Istanbul
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Coventry
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Glasgow
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Hull
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Liverpool
Country [142] 0 0
United Kingdom
State/province [142] 0 0
London
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Luton
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novo Nordisk A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.

The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.

Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).
Trial website
https://clinicaltrials.gov/study/NCT01272219
Trial related presentations / publications
Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes. 2016 Aug;6(4):233-42. doi: 10.1111/cob.12146. Epub 2016 May 19.
Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. Clin Pharmacokinet. 2016 Nov;55(11):1413-1422. doi: 10.1007/s40262-016-0410-7.
O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, Claudius B, Pi-Sunyer X; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 Nov;22(11):1277-1287. doi: 10.4158/EP151181.OR. Epub 2016 Aug 2.
Fujioka K, O'Neil PM, Davies M, Greenway F, C W Lau D, Claudius B, Skjoth TV, Bjorn Jensen C, P H Wilding J. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 Nov;24(11):2278-2288. doi: 10.1002/oby.21629.
Bays H, Pi-Sunyer X, Hemmingsson JU, Claudius B, Jensen CB, Van Gaal L. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin. 2017 Feb;33(2):225-229. doi: 10.1080/03007995.2016.1251892. Epub 2016 Nov 6.
Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab. 2016 May;18(5):491-9. doi: 10.1111/dom.12639. Epub 2016 Mar 1.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.
McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 2016;26(1):30-6. doi: 10.1080/10543406.2015.1094814.
Ard J, Cannon A, Lewis CE, Lofton H, Vang Skjoth T, Stevenin B, Pi-Sunyer X. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes Obes Metab. 2016 Apr;18(4):430-5. doi: 10.1111/dom.12632. Epub 2016 Feb 11.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjoth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Erratum In: Lancet. 2017 Apr 8;389(10077):1398. doi: 10.1016/S0140-6736(17)30705-5.
von Scholten BJ, Davies MJ, Persson F, Hansen TW, Madsbad S, Endahl L, Jepsen CH, Rossing P. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. J Diabetes Complications. 2017 Jul;31(7):1164-1168. doi: 10.1016/j.jdiacomp.2017.04.003. Epub 2017 Apr 11.
O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21.
Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018 Mar;20(3):734-739. doi: 10.1111/dom.13125. Epub 2017 Nov 1.
Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018 Feb;8(1):1-10. doi: 10.1111/cob.12226. Epub 2017 Oct 16.
le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m(2): A Post-hoc Analysis. Obes Facts. 2017;10(6):531-544. doi: 10.1159/000478099. Epub 2017 Nov 17.
Williams DM, Staff M, Bain SC, Min T. Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. touchREV Endocrinol. 2022 Mar;18(1):43-48. doi: 10.17925/EE.2022.18.1.43. Epub 2022 Mar 18.
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Registry GCR, 1452
Address 0 0
Novo Nordisk A/S
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01272219